FDA Supplement GMP Warnings Cite Specification Failings
This article was originally published in The Tan Sheet
Executive Summary
Setting and confirming specifications for ingredients and for manufacturing processes continue to be a problem for dietary supplement firms, some of which fail to include adequate information on how they will remedy their problems when they respond to FDA inspectors’ findings.
You may also be interested in...
Undisclosed Allergen, Caffeine Claims Prompt Supplement Recalls
Firms marketing supplements found to contain steroid ingredients also are recalling products.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.